This uncontrolled study suggests that CD25+ CTCL can respond to this new fusion toxin but

What are the effects of antibody and toxin therapies in mycosis fungoides/Sezary syndrome?

the duration of response is short. However, patients recruited for this trial were heavily pretreated, suggesting that this is likely to be a useful additional therapy for CTCL patients with resistant disease, despite potential adverse effects. A randomised placebo-controlled trial in patients with stage IB/IIB/III mycosis fungoides who have undergone fewer than three previous treatments is ongoing.

0 0

Post a comment